|
Index | - | P/E | - | EPS (ttm) | -6.84 | Insider Own | 2.53% | Shs Outstand | 7.93M | Perf Week | -6.09% |
Market Cap | 8.20M | Forward P/E | - | EPS next Y | -0.95 | Insider Trans | 0.00% | Shs Float | 7.23M | Perf Month | -6.09% |
Income | -29.70M | PEG | - | EPS next Q | -1.10 | Inst Own | 3.50% | Short Float / Ratio | 4.69% / 0.11 | Perf Quarter | -44.04% |
Sales | 0.30M | P/S | 27.32 | EPS this Y | 52.00% | Inst Trans | 3.10% | Short Interest | 0.34M | Perf Half Y | -72.89% |
Book/sh | -0.57 | P/B | - | EPS next Y | 26.50% | ROA | -242.10% | Target Price | 18.90 | Perf Year | -76.41% |
Cash/sh | 0.41 | P/C | 2.64 | EPS next 5Y | - | ROE | -513.60% | 52W Range | 0.91 - 9.37 | Perf YTD | -6.09% |
Dividend | - | P/FCF | - | EPS past 5Y | 53.00% | ROI | - | 52W High | -88.48% | Beta | 0.58 |
Dividend % | - | Quick Ratio | 0.70 | Sales past 5Y | -61.50% | Gross Margin | - | 52W Low | 18.42% | ATR | 0.12 |
Employees | 12 | Current Ratio | 0.70 | Sales Q/Q | -80.00% | Oper. Margin | - | RSI (14) | 43.13 | Volatility | 9.86% 11.30% |
Optionable | No | Debt/Eq | - | EPS Q/Q | 31.80% | Profit Margin | - | Rel Volume | 0.29 | Prev Close | 1.15 |
Shortable | Yes | LT Debt/Eq | - | Earnings | - | Payout | - | Avg Volume | 2.99M | Price | 1.08 |
Recom | 1.50 | SMA20 | -13.29% | SMA50 | -3.77% | SMA200 | -58.46% | Volume | 861,293 | Change | -6.09% |
![]() | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
![]() | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
![]() | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sonnet BioTherapeutics Holdings, Inc., a clinical stage oncology-focused biotechnology company, develops platform for biologic medicines of single or bispecific action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its lead candidate is SON-1010, a fully human version of interleukin 12 for the treatment non-small cell lung cancer, and head and neck cancer. The company is also developing SON-080, a fully human version of interleukin 6 for chemotherapy-induced peripheral neuropathy and diabetic peripheral neuropathy. It has a license agreement with New Life Therapeutics PTE, LTD. to develop and commercialize pharmaceutical preparations containing a specific recombinant human interleukin 6. Sonnet BioTherapeutics Holdings, Inc. is based in Princeton, New Jersey. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
![]() | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
![]() |
open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR |
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite